Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.43 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | COMT | P21964 | 1/20 | 0.43 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 3/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 3/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16689664 | 0.94 | MEN1 (0.42) | MEN1KMT2ALMNAABCC3ABCC4 | |
| SCHEMBL16689655 | 0.89 | FTO (0.57) | MEN1KMT2ALMNAABCC3ABCC4 | |
| SCHEMBL16690920 | 0.82 | MEN1 (0.47) | MEN1KMT2ALMNAABCC3ABCC4 | |
| SCHEMBL4609366 | 0.77 | MEN1 (0.68) | MEN1KMT2ALMNAABCC3ABCC4 | |
| SCHEMBL4609378 | 0.77 | MEN1 (0.68) | MEN1KMT2ALMNAABCC3ABCC4 | |
| SCHEMBL16690921 | 0.77 | MEN1 (0.59) | MEN1KMT2ALMNAABCC3ABCC4 | |
| SCHEMBL16690919 | 0.76 | MEN1 (0.58) | MEN1KMT2ALMNAABCC3ABCC4 | |
| SCHEMBL16689665 | 0.75 | KMT2A (0.47) | MEN1KMT2ALMNAABCC3ABCC4 | |
| SCHEMBL16690922 | 0.73 | MEN1 (0.52) | MEN1KMT2ALMNAABCC3ABCC4 | |
| SCHEMBL16689667 | 0.70 | FTO (0.65) | MEN1KMT2ALMNAABCC3ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266823-B2 | Compositions and methods for the treatment of parkinson's disease | CELLIX BIO PRIVATE LIMITED (IN) | 2016-02-23 | — | — | US | disclosed |
| US-20150126591-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | CELLIX BIO PRIVATE LIMITED (IN) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126591-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | PARK7, HTT, SNCA | MEN1 1288/4885KMT2A 4311/4885LMNA 3665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.